Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFY: Denufosol Extension in Cystic Fibrosis
NCT00846781Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of denufosol tetrasodium in cystic fibrosis (CF), sponsored by Merck & Co. Primary endpoint: Rate of change in lung function, as measured by change in FEV1 at 160 weeks. Started Feb 2009; status: terminated.
02
Drugs
denufosol tetrasodium
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00846781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846781.